Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.93 USD
0.00 (0.00%)
Updated May 9, 2024 04:00 PM ET
After-Market: $3.94 +0.01 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum C VGM
Brokerage Reports
0 items in cart
Atea Pharmaceuticals, Inc. [AVIR]
Reports for Purchase
Showing records 1 - 16 ( 16 total )
Company: Atea Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Q1 FY18 Recap: Transition to VXRT Set to Close by March 2018; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Vaxart Reverse Merges Into Aviragen Shell; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
3QFY17 Results: Strategic Review Seeks to Salvage Remaining Value; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Complete Failure of SPIRITUS Leaves Little Visibility to Value; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
2QFY17 Recap: Key Phase 2b SPIRITUS Data Imminent; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
1QFY17 Recap: Enrollment Into Both Phase 2 Studies SPIRITUS And HRV Challenge Complete; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
4Q Recap: Top-line Data Readouts of Phase 2 SPIRITUS and RSV Challenge at Year End; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Novel Direct-Acting Antivirals Focused on Respiratory Infections; Initiate Buy, $5 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
Company: VAXART, INC.
Industry: Medical - Biomedical and Genetics
|